Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of Sutimlimab in Healthy Volunteers and Complement-mediated Disorders
NCT02502903Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2015
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sutimlimab in cold agglutinin disease (CAD), Bullous Pemphigoid (BP), warm autoimmune hemolytic anemia (wAIHA) and 1 more (4 arms), sponsored by Sanofi. Primary endpoint: Drug-related Adverse Event profile at 6 weeks. Started Jul 2015; status: completed.
02
Drugs
sutimlimab
03
Conditions
cold agglutinin disease (CAD)Bullous Pemphigoid (BP)warm autoimmune hemolytic anemia (wAIHA)antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02502903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502903.